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without chronic GVHD was 97% and 76%, respectively
(p¼0.002). The cumulative incidence of squamous cell
carcinoma (SCC) at 10yswas 8% and at 15yswas 14%. SCC was
more common in those who reported chronic GVHD
compared to those without chronic GVHD (14% vs. 4%,
p¼0.03). Endocrine dysfunction was common with
hypogonadism in 40% of patients and hypothyroidism in 25%.
Normal pregnancies occurred in 4 females with normal
offspring. Neurological, auditory, visual, pulmonary, hepatic
and renal complications were disease-related or transplant
procedure but occurred at substantially lower frequencies.
There were 20 deaths (13%) that occurred after 2 years. SCC
was the predominant cause of death (n¼8). Other causes of
death include, chronic GVHD (n¼6), rejection (n¼2),
pulmonary complications (n¼2), urinary sepsis (n¼1) and
hepatitis C (n¼1). In summary, most long-term survivors are
disease-free and lead functional lives. However, for those
patients with late complications of transplantation or its
effects, efforts must be directed at lowering morbidity and
mortality.62
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Allogeneic hematopoietic cell transplantation (allo HCT)
survivors are at risk for long-term mortality from late
complications. Low socioeconomic status (SES) has been
shown to be associated with health care disparities including
poor access and adverse outcomes in a variety of health
conditions. Early post-transplant care is typically well
coordinated through the patients transplant center.
However, as patients transition back to their community
providers, it is possible that patients with less resources and
poor access to healthcare would be at higher risk for
complications and mortality. Hence, we hypothesized that
SES would be associated with survival and non-relapseFigure. Overall survival by SES in 1 year allogeneic HCT survivorsmortality (NRM) in long-term survivors after allo HCT. We
studied 283 consecutive allo HCT recipients transplanted
between 2003 and 2012 who had survived for at least 1 year
in remission. Median annual household income was
estimated using Census tract data and from ZIP code of
residence at the time of transplant. SES categories were
determined by recursive partitioning analysis and were
categorized into low SES (<$51,000/yr, N¼203) and high SES
($51,000/yr, N¼80). Low SES patients were more likely to
be of non-White race (10% vs. 1%), otherwise there were no
notable differences between the two cohorts, including
diagnosis, disease status, HCT-Comorbidity Index scores,
donor source, graft source and conditioning regimen
intensity. In univariate analysis, low SES patients had
signiﬁcantly worse survival (Figure) and NRM but
comparable incidence of relapse mortality. In multivariate
analyses that adjusted for patient, disease and transplant
characteristics, patients with low SES had signiﬁcantly
higher risks of all-cause mortality (HR 1.98, 95% CI 1.16-3.37,
p¼0.012) and NRM (HR 2.22, 95% CI 1.09-4.50, p¼0.028), but
similar risks of relapse mortality (HR 1.01, 95% CI 0.44-2.34,
p¼0.97) compared to high SES patients. Common causes of
death in low SES and high SES patients included disease
relapse (39% vs 47%), infections (20% vs 12%), organ toxicity
(17% vs 18%) and chronic graft-versus-host disease (11% vs
18%). In conclusion, 1 year allo HCT survivors with low SES
have inferior overall survival that is driven by higher NRM
compared to patients with high SES. More research is needed
to understand the reasons for these health care disparities
and identify interventions to mitigate them.63
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Background: Venous Thromboembolism (VTE) is a common
late effect after Hematopoietic Stem Cell Transplant with
wide variation in reported frequency of incidence (1-20% of
patients). There is lack of data with respect to risks and
outcomes of VTE, unlike sinusoidal obstruction syndromes
(SOS) for which adequate literature is available. Therefore,
optimal approach for prevention and management of VTE in
HSCT patients is unknown. We sought to conduct a
meta-analysis of VTE incidence and evaluate its risk factors in
HSCT patients.
Methods: A comprehensive search of several databases from
each database’s earliest inception to June 2, 2014 in any
language was conducted by an experienced medical
librarian. The databases included Ovid Medline In-Process &
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE,
Ovid CCT and Scopus. To avoid publication bias, we also
searched annual meeting abstracts from ASBMT, EBMT, ASH,
SIOP, and ISTH. The electronic search generated 755 articles.
Only 34 studies met the strict selection criteria. Case reports,
review articles, meta-analysis, postmortem reports, and
solid organ transplants were excluded. Two investigators
independently analyzed the studies for ﬁnal selection. Both
autologous and allogeneic HSCTs were included for any
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78 S75indication. SOS and thrombotic microangiopathy cases
were excluded from the analysis. Only Deep Venous
Thrombosis and Pulmonary embolism were included in the
analysis.
Results: Among the ﬁnal 34 studies with adequate data for
analysis, N was 8353. 522 patients developed DVT or PE in
the cohort giving an incident rate of 6.12%. Quality appraisal
was performed for clinical trials using the Cochrane Risk of
Bias tool, which indicated poor quality of reporting in
majority of trials with possibility of introducing bias. A
meta-regression model could not be constructed due to
non-uniform reporting of the outcome of interest and
because of signiﬁcant methodologic variation between the
studies. Among the patients receiving immunomodulatory
(IMiD) therapy post-HSCT (n¼703), 22.7% developed VTE.
Chronic graft versus host disease did not affect the rates of
VTE; although most of the studies in the ﬁnal cohort did not
report the cGVHD incidence. VTE incidence in autologous
HSCT and allogeneic HSCT was 9.43% (196/2078) and 4.61%
(180/3902) respectively [data missing or not reported for
rest].
Conclusions: VTE can be life-threatening late complication
of HSCT with substantial number of patients developing PE
or DVT post HSCT. Results of our study with a large sample
size indicate a substantial risk of VTE with IMiD usage in
HSCT patients. Further studies from large database would
be helpful in deciphering the associations of VTE with
GVHD and establishing guidelines for prophylaxis and
management.64
A Phase II Study of Bandage Contact Lenses for Ocular
Graft-Versus-Host Disease
Yoshihiro Inamoto 1, Yichen Sun 2, Peng Li 3,
Mary E.D. Flowers 1, Paul J. Martin 1, Paul A. Carpenter 1,
Ruikang Wang 2,3, Xiaoyu Chai 1, Barry E. Storer 1,
Tueng T. Shen 2,3, Stephanie J. Lee 1. 1 Clinical Research Division,
Fred Hutchinson Cancer Research Center, Seattle, WA;
2Ophthalmology, University of Washington, Seattle, WA;
3 Bioengineering, University of Washington, Seattle, WA
Background: Ocular involvement occurs in more than half of
patients with chronic graft-versus-host disease (GVHD),
compromising both quality of life and function. Ocular GVHD
can be refractory to treatment once dry eye syndrome is
established. A bandage contact lens (BCL) is a widely
available, disposable, soft contact lens used for the treatmentof a diseased or injured cornea. We performed a phase II trial
of BCLs for patients with ocular GVHD.
Methods: Eligibility criteria included adult patients with
moderate to severe ocular GVHD according to NIH consensus
criteria. BCLs were replaced every 2-4 weeks. Patients were
instructed to use daily antibiotic eye drops to prevent ocular
infection. Patients completed standardized symptom
questionnaires at enrollment and at 2 weeks, 4 weeks and 3
months after placement of BCLs. The primary endpoint was
symptom improvement by the Lee eye subscale after 2weeks
of therapy. Secondary endpoints included improvement in
ocular surface disease index (OSDI), 11-point eye
symptom rating and ophthalmologic assessments during 3
months of therapy. For patient-reported measures, higher
scores indicate worse symptoms. Measures at follow-up
assessments were compared with those at enrollment by
paired t-test. Patients gave written consent to participate in
the study and the Institutional Review Board approved the
study.
Results: Nineteen patients participated in the study from
August 2012 to August 2014. Median agewas 55 years (range,
32-75), and median time from transplantation to enrollment
was 36.5 months (range, 8-157 months). Fourteen patients
had moderate ocular GVHD and 5 had severe ocular GVHD at
enrollment. The mean Lee eye subscale score at enrollment
was 75, and the score improved signiﬁcantly at 2 weeks
(mean 63; p¼0.02) and thereafter (Figure). The mean OSDI
score at enrollment was 55.5, and the score improved
signiﬁcantly at 2 weeks (mean 37.1; p¼0.002) and
thereafter. According to the Lee eye subscale, 44% showed
clinically meaningful improvement at 2 weeks, 53% at 4
weeks and 54% at 3 months. According to ophthalmologic
examination at 2 weeks, ocular GVHD showed 89%
improvement, 5% stability and 5% worsening. At 2 weeks,
one patient stopped BCLs due to discomfort, and another
patient did not wear one lens after it fell out. At 3 months,
2 patients stopped using BCLs after eye symptoms had
sufﬁciently improved, and another patient stopped
using BCL due to blurred vision. The most frequent
adverse events within 3 months after BCL placement
included foreign body sensation (74%), swollen eyelids
(26%) and excessive tearing (11%). No ocular infection or
other corneal complications were documented during the
3 months.
Conclusion: BCLs are a safe, tolerable and effective
treatment that improves symptoms of moderate to severe
ocular GVHD in approximately 50% of patients. This study
was registered at www.clinicaltrials.gov as NCT01616056.
